Mercer Global Advisors
INDV icon

Mercer Global Advisors’s Indivior Pharmaceuticals INDV Stock Holding History

Mercer Global Advisors’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,635
Closed -$274K – 3288
2025
Q4 		$274K Buy
+7,635
New +$233K ﹤0.01% 2307

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Mercer Global Advisors's INDV Position: Q1 2026 in Review

Mercer Global Advisors sold out of Indivior Pharmaceuticals (INDV) in Q1 2026, closing a stake of 7,635 shares — an estimated $274K sold.

Mercer Global Advisors first reported a position in INDV in Q4 2025 and held it in 1 quarter. The position peaked at $274K in Q4 2025. 289 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

  • Mercer Global Advisors reported no remaining Indivior Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Mercer Global Advisors sold 7,635 Indivior Pharmaceuticals shares in Q1 2026, an estimated $274K.
  • Mercer Global Advisors first reported a position in Indivior Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Mercer Global Advisors's Indivior Pharmaceuticals position peaked at $274K in Q4 2025.
  • 289 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.